Selection of GP. Mur antigen‐negative RBC for blood recipients with anti‐‘Mi^a’ records decreases transfusion reaction rates in Taiwan

Abstract

Selection of GP. Mur-negative RBC for transfusion to patients with anti-'Mi ' records could decrease the rate of transfusion reaction and antibody boosting. This procedure should be incorporated into blood bank routines in areas where anti-'Mi ' is prevalent.

Fetal inheritance of GP*Mur causing severe HDFN in an unrecognized case of maternal alloimmunization

“…Figure 1A summarizes the number of reports and antibody specificities. 5,[9][10][11][12][13][14][15][16][17][18][19][20][21] Obstetric cases are restricted to patients and their partners of Southeast Asian ancestry. The Mur antigen has a prevalence of less than 0.1% in whites and blacks but is 3% to 10% in Southeast Asian populations (Fig.…”

“…Some transfusion incompatibility and obstetric problems are associated with alloantibodies against MNS hybrid glycophorin antigens. Figure A summarizes the number of reports and antibody specificities . Obstetric cases are restricted to patients and their partners of Southeast Asian ancestry.…”

Hybrid glycophorin and red blood cell antigen genotyping in Asian American type O blood donors with Mia phenotype

“…RBCs from GP.Mur‐positive individuals have been used as reagent cells for screening Mi a ‐specific antibodies in Taiwan and Hong Kong . Use of RBCs from GP.Mur homozygote donors could help in detecting weak antibodies.…”

The prevalence, immunogenicity, and evanescence of alloantibodies to MUT and Mur antigens of GP.Mur red blood cells in a Southeast Asian patient cohort

“…The transient nature of anti‐MUT and ‐Mur posttransfusion would also have an impact on its identification and the choice of screening cells, as the Mur antigen has been shown to have a dosage effect, and therefore homozygous GP.Mur screening cells would be recommended to avoid neglecting weak antibodies . The routine supply of GP.Mur negative RBC units for patients identified to have anti‐Mi a has also been reported to reduce incidences of transfusion reactions, thereby providing indirect evidence for utility of identifying GP.Mur‐directed alloantibodies in affected populations . More consistent and widespread availability of potent monoclonal antibodies for GP.Mur phenotyping as well as applying molecular typing methods for identification of the polymorphism would increasingly facilitate the selection of appropriate antigen‐negative RBC units …”

“…2 The routine supply of GP.Mur negative RBC units for patients identified to have anti-Mi a has also been reported to reduce incidences of transfusion reactions, thereby providing indirect evidence for utility of identifying GP.Murdirected alloantibodies in affected populations. 23 More consistent and widespread availability of potent monoclonal antibodies for GP.Mur phenotyping as well as applying molecular typing methods for identification of the polymorphism would increasingly facilitate the selection of appropriate antigen-negative RBC units. 3,24 Several approaches and refinements based on antigen and corresponding antibody prevalence have been proposed to estimate absolute immunogenicity of RBC antigens.…”